Alpha 1 Antitrypsin AAT at Dr. Essa Lab

Alpha 1 Antitrypsin AAT at Dr. Essa Lab

Alpha-1 antitrypsin (AAT) is a vital glycoprotein synthesized primarily by hepatocytes in the liver and secreted into the bloodstream. Its primary physiological role is to act as a major protease inhibitor, specifically targeting and neutralizing neutrophil elastase in the lower respiratory tract. Neutrophil elastase is a powerful enzyme released by white blood cells to fight infections; however, without the regulatory control of AAT, it can degrade the delicate elastic fibers of the alveolar walls, leading to progressive pulmonary tissue destruction. The Alpha 1 Antitrypsin AAT test is a highly specialized laboratory investigation designed to measure the concentration of this protective protein in a patient’s blood. At Dr. Essa Lab, this test is performed using state-of-the-art automated clinical chemistry analyzers, utilizing advanced immunoturbidimetric or nephelometric techniques to ensure maximum diagnostic precision.

Understanding AAT levels is of paramount clinical importance in identifying Alpha-1 Antitrypsin Deficiency (AATD), an underdiagnosed hereditary genetic disorder. AATD is characterized by codominant transmission of mutated alleles of the SERPINA1 gene. When these mutations occur, they cause the AAT protein to misfold and aggregate within the endoplasmic reticulum of hepatocytes, preventing its release into the circulation. This results in a dual pathological consequence: a severe deficiency of protective AAT in the lungs, which leads to early-onset pulmonary emphysema, and a toxic accumulation of abnormal protein in the liver, which can cause neonatal cholestasis, chronic hepatitis, liver cirrhosis, and an increased risk of hepatocellular carcinoma. By providing accurate quantification of serum AAT, Dr. Essa Lab assists clinicians in Karachi and across Pakistan in diagnosing this complex condition early, enabling timely therapeutic interventions such as enzyme replacement therapy and lifestyle modifications to preserve lung and liver function.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of your Alpha 1 Antitrypsin AAT test results at Dr. Essa Lab, patients are advised to follow specific preparation guidelines. While fasting is not strictly mandatory for a standalone AAT test, a fasting period of 8 to 12 hours is highly recommended if the test is ordered as part of a comprehensive liver panel or lipid profile. Patients must inform their healthcare provider of all current medications, vitamins, and dietary supplements. It is particularly important to report the use of oral contraceptive pills or hormone replacement therapy, as estrogens can physiologically elevate serum AAT levels, potentially masking a mild deficiency. Additionally, because AAT is an acute-phase reactant, any active infection, inflammatory condition, or recent surgical procedure should be disclosed, as these states can transiently elevate AAT levels and complicate the interpretation of the results.

During the Procedure

The collection of the blood specimen for the Alpha 1 Antitrypsin AAT test is a routine, safe, and quick outpatient procedure. Upon arriving at one of Dr. Essa Lab’s modern collection centers, a trained phlebotomist will verify your identity and explain the procedure. You will be seated comfortably, and the phlebotomist will select a suitable vein, typically in the antecubital fossa of your arm. The skin over the vein is thoroughly cleansed with an antiseptic solution to prevent contamination. A sterile, single-use needle is gently inserted into the vein to draw a small volume of blood into a gold-top (serum separator) or red-top vacuum tube. You may feel a brief, mild pinch as the needle enters the skin. Once the sample is collected, the needle is withdrawn, and gentle pressure is applied to the puncture site with a sterile cotton ball, followed by the application of a bandage. The entire process takes less than five minutes, and patients can immediately resume their daily activities.

When is a Alpha 1 Antitrypsin AAT Performed?

Early-Onset Emphysema and COPD

Physicians frequently request the Alpha 1 Antitrypsin AAT test when a patient presents with symptoms of chronic obstructive pulmonary disease (COPD) or emphysema at an unusually young age, typically under 45 years. Classic symptoms include progressive dyspnea (shortness of breath), chronic cough, wheezing, and sputum production. When these respiratory symptoms occur in individuals with no history of smoking or minimal exposure to environmental irritants, clinical suspicion for genetic AAT deficiency rises significantly. The test helps differentiate hereditary emphysema from standard tobacco-induced lung disease, allowing for targeted therapies such as augmentation therapy with purified human AAT.

Unexplained Liver Disease and Cirrhosis

The test is highly indicated for patients of any age who exhibit unexplained signs of liver dysfunction or chronic liver disease. Clinical symptoms may include persistent jaundice, dark urine, pale stools, abdominal swelling (ascites), pruritus (itching), and unexplained elevations in liver enzymes (ALT and AST). In adults, AAT deficiency can present as cryptogenic cirrhosis, portal hypertension, or chronic active hepatitis. By measuring serum AAT levels, hepatologists can determine if the underlying hepatic pathology is due to the intracellular accumulation of abnormal, misfolded AAT proteins, which triggers hepatocyte apoptosis and progressive fibrogenesis.

Family History of AAT Deficiency

Genetic screening and risk assessment are crucial indications for performing the Alpha 1 Antitrypsin AAT test. If an individual is diagnosed with AAT deficiency, their first-degree relatives, including siblings, children, and parents, should be screened. Many individuals carrying mutated alleles may remain asymptomatic for years while progressive, silent tissue damage occurs in their lungs or liver. Early detection through familial screening at Dr. Essa Lab allows relatives to adopt preventive measures, such as strict avoidance of tobacco smoke and occupational dust, and to receive regular clinical monitoring.

Neonatal Cholestasis

In pediatrics, the Alpha 1 Antitrypsin AAT test is a critical diagnostic tool for evaluating newborns and infants presenting with prolonged neonatal jaundice or cholestasis. Symptoms such as yellowing of the skin and sclera, hepatomegaly (enlarged liver), and poor weight gain beyond the first two weeks of life warrant immediate investigation. AAT deficiency is the most common genetic cause of liver disease in children. Identifying the deficiency early is essential for managing nutritional requirements, monitoring for portal hypertension, and planning long-term care, which may occasionally include liver transplantation in severe cases.

Panniculitis and Vascular Inflammation

A less common but highly specific clinical indication for the AAT test is the presence of necrotizing panniculitis, an inflammatory skin condition characterized by painful, ulcerating subcutaneous nodules, typically on the thighs and buttocks. Additionally, patients presenting with systemic vasculitis, particularly granulomatosis with polyangiitis (formerly Wegener’s granulomatosis), may be evaluated for AAT levels. Because AAT plays a key role in modulating systemic inflammatory cascades and inhibiting tissue-degrading proteases, severe deficiency states can manifest as these rare cutaneous and vascular inflammatory disorders.

What Does a Alpha 1 Antitrypsin AAT Detect?

The Alpha 1 Antitrypsin AAT test is highly sensitive and capable of detecting a wide range of clinical states, genetic predispositions, and physiological responses. Specifically, the test detects:

• Severe Alpha-1 Antitrypsin Deficiency: Extremely low serum levels, typically associated with the homozygous PiZZ genotype, indicating a high risk of early-onset emphysema and liver disease.
• Moderate Alpha-1 Antitrypsin Deficiency: Reduced serum levels often found in heterozygous individuals (such as PiSZ or PiMZ genotypes) who may be at risk under environmental stress.
• Normal Circulating AAT Levels: Levels within the established reference range, suggesting adequate protease inhibitor capacity and ruling out primary deficiency.
• Acute-Phase Reactant Elevation: Significantly elevated AAT levels in response to acute infections, systemic inflammation, tissue necrosis, or trauma.
• Estrogen-Induced Elevation: Physiological increases in AAT concentration due to pregnancy, oral contraceptive use, or hormone replacement therapy.
• Heterozygous Carrier Status: Identification of individuals who carry one normal and one mutated allele, useful for genetic counseling.
• Risk of Pulmonary Alveolar Destruction: Low levels indicate insufficient protection against neutrophil elastase, predicting a high risk of lung tissue breakdown.
• Intracellular Hepatic Accumulation Risk: Low serum levels combined with liver symptoms suggest that abnormal AAT is trapped inside hepatocytes.
• Neonatal Giant Cell Hepatitis: Low levels in infants pointing to AATD as the underlying cause of neonatal liver inflammation.
• Cryptogenic Cirrhosis Etiology: Explains the root cause of liver scarring in patients where viral, autoimmune, and alcoholic causes have been ruled out.
• Predisposition to Bronchiectasis: Detects deficiency states that contribute to the chronic dilation of bronchi due to uncontrolled elastase activity.
• Necrotizing Panniculitis Association: Confirms whether painful subcutaneous skin nodules are linked to a lack of protease inhibition.
• Granulomatosis with Polyangiitis Risk: Identifies patients with low anti-protease activity who may experience more severe vasculitic complications.
• Advanced Hepatic Parenchymal Failure: Decreased AAT levels resulting from the liver’s overall inability to synthesize proteins due to end-stage cirrhosis.
• Protein-Losing Enteropathy: Falsely low AAT levels caused by excessive loss of proteins through the gastrointestinal tract.
• Nephrotic Syndrome: Reduced serum AAT levels due to significant renal protein excretion in urine.
• Malnutrition-Induced Protein Deficiency: Low circulating levels of AAT due to severe dietary protein deprivation.
• Post-Operative Inflammatory Response: Transiently elevated levels following major surgical interventions as part of the body’s healing cascade.
• Active Rheumatoid Arthritis: Elevated levels reflecting systemic joint and connective tissue inflammation.
• Malignancy-Associated Inflammation: Increased AAT levels triggered by certain cancers that stimulate acute-phase protein synthesis.
• Chronic Active Hepatitis: Fluctuating or abnormal levels indicating ongoing, progressive liver inflammation.
• Hepatocellular Carcinoma Risk: Low serum levels due to genetic mutations that predispose individuals to primary liver cancer.
• Asymptomatic Carrier Identification: Detects individuals with borderline levels who require lifestyle counseling to prevent future lung damage.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is widely recognized across Karachi and Pakistan for its commitment to providing rapid, highly accurate, and accessible diagnostic services. The turnaround time for the Alpha 1 Antitrypsin AAT test is typically within 24 to 48 hours from the time of sample collection. Because this is a specialized biochemical assay requiring precise calibration and quality control, our expert pathologists meticulously review each batch of results to ensure clinical accuracy before release.

To make the diagnostic journey as seamless as possible for our patients, Dr. Essa Lab offers multiple convenient ways to access test reports. Once your report is finalized and signed off by our consultant pathologist, you will receive an automated SMS notification containing a direct link to download your report in PDF format. Patients can also log on to the secure online portal on the official Dr. Essa Lab website using their unique patient ID and password. For those who prefer physical copies, reports can be collected directly from any of our conveniently located collection centers, or you can opt for our reliable home delivery service. This digital-first approach ensures that you and your referring physician receive critical diagnostic data without delay, facilitating prompt clinical decision-making.

Alpha 1 Antitrypsin AAT Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Serum AAT Concentration	90 to 200 mg/dL (may vary slightly by lab methodology)	Decreased (<90 mg/dL) in genetic deficiency or protein loss; Elevated (>200 mg/dL) in acute inflammation.
Phenotype (Pi Type)	PiMM (Normal phenotype, representing two normal M alleles)	PiZZ (Severe deficiency), PiSZ (Moderate deficiency), PiMZ (Mild deficiency/carrier state).
Pulmonary Function Correlation	Normal spirometry and lung volumes; no evidence of emphysema	Obstructive lung pattern, reduced FEV1, basilar emphysema, and impaired gas exchange (DLCO).
Hepatic Enzyme Correlation	Normal ALT, AST, GGT, and Bilirubin levels	Elevated transaminases, elevated direct bilirubin, and prolonged prothrombin time indicating liver injury.
Pediatric Cholestasis Markers	Normal biliary excretion; absence of neonatal jaundice	Prolonged conjugated hyperbilirubinemia, indicating neonatal giant cell hepatitis or biliary obstruction.
Acute Phase Reactant Status	Baseline levels stable in the absence of active systemic disease	Markedly elevated levels during active bacterial infections, rheumatoid arthritis flares, or post-surgery.
Genetic Allele Configuration	Wild-type homozygous alleles (normal SERPINA1 gene sequence)	Heterozygous or homozygous mutations (Z, S, or rare null alleles) confirming genetic deficiency.
Clinical Risk Stratification	Low risk for early-onset COPD and chronic liver disease	High risk for panacinar emphysema, bronchiectasis, liver cirrhosis, and hepatocellular carcinoma.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Alpha 1 Antitrypsin AAT?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified consultant pathologists, biochemists, and technologists specializing in genetic and metabolic disorders.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the diagnostic process, from sample collection to reporting.
• Quality Diagnostic Services: Dr. Essa Lab utilizes state-of-the-art, fully automated analyzers and adheres to strict international quality control protocols.
• Professional Reporting: Every report is meticulously verified and signed by a consultant pathologist, ensuring clinical reliability and accuracy.
• Modern Diagnostic Approach: We employ advanced immunoturbidimetric and nephelometric methodologies to deliver precise quantitative results.
• Comfortable Environment: Our diagnostic centers are designed to provide a clean, hygienic, and welcoming atmosphere for all patients.
• Convenient Location: With an extensive network of collection points across Karachi and other major cities, accessing our services is highly convenient.
• Commitment to Accurate Diagnosis: Established in 1987, Dr. Essa Lab has built decades of trust by consistently delivering accurate, timely, and affordable diagnostic solutions.